If your Brickell business has an FDA question that cannot wait — an FDA compliance matter, an inspection, a deadline — start with what the rules actually require. Brickell is the financial capital of Latin American trade — the banks that finance Miami’s imports, the regional headquarters that direct them, and the executives who make product and market-entry decisions for the hemisphere all sit within a few blocks. Garg Law’s Miami office is here, at 1221 Brickell Avenue, in the middle of that corridor. The companies steering FDA-regulated product lines from Brickell towers need regulatory answers at deal speed — and the office handling them is on the same street.
The short answer
FDA compliance is a lifecycle discipline: classification, registrations and listings, labeling and claims, manufacturing controls, import requirements, and the enforcement that follows when any of them slip. Counsel that works across every FDA-regulated product category — foods, supplements, cosmetics, OTC drugs, devices — catches the cross-cutting problems single-category advisors miss.
What an FDA compliance matter really involves
FDA regulates most of what Miami imports and sells: foods and beverages, dietary supplements, cosmetics, over-the-counter drugs, medical devices, and more. Each category carries its own regime — FSMA’s preventive controls and supplier verification for food, MoCRA for cosmetics, the monograph system for OTC drugs, registration and listing for devices — but a company’s risk runs across all of them at once.
The recurring compliance questions are classification (is this product a food, supplement, cosmetic or drug — often decided by its claims), registration and listing obligations, labeling and advertising review, manufacturing and supplier controls, and import compliance for everything sourced abroad. Getting classification wrong contaminates every downstream decision.
Enforcement is the other half: FDA inspections and Form 483 responses, warning letters, recalls, import actions and, for serious matters, injunctions and seizures. Companies that treat a warning letter as a template exercise learn how quickly FDA escalates; companies with counsel respond in the agency’s language, with corrective actions FDA credits.
How Garg Law handles it
- Regulatory assessment across your product portfolio: classification, applicable regimes, and current-state gaps
- Registration, listing and facility-obligation audit — what FDA thinks it knows about you versus reality
- Labeling and claims review before printing and campaigns, not after a warning letter
- Inspection readiness and response: 483 answers, corrective-action plans, warning-letter strategy
- Ongoing counsel as products, suppliers and regulations change — FDA compliance is maintained, not achieved
Why Brickell operators call us
The work around Brickell — international banking and trade finance, multinational regional headquarters, consumer brand offices, legal and professional services, import/export holding companies — is FDA-regulated at nearly every turn, and matters here move on Miami’s financial district, home to the banks, trade finance desks and regional headquarters that fund and direct hemispheric trade. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.
What not to do
- Classifying products by marketing intuition instead of regulatory analysis of their claims
- Assuming a co-packer’s or supplier’s registrations cover your obligations
- Copying a competitor’s label and inheriting its violations
- Answering a Form 483 or warning letter with promises instead of documented corrective actions
- Building compliance for one product category while importing across five
Frequently asked questions
What does an FDA compliance attorney actually do?
Everything between product concept and enforcement defense: classification opinions, registrations and listings, label and claims review, manufacturing and supplier compliance programs, import strategy, and responses to inspections, warning letters and recalls. The value is preventing the second half by doing the first half well.
How do I know which FDA rules apply to my product?
Classification drives everything, and claims drive classification — the same formulation can be a cosmetic or an unapproved drug depending on what the label promises. A classification analysis against the Food, Drug, and Cosmetic Act’s definitions is the first step for any new product.
What should I do when FDA shows up to inspect?
Cooperate professionally, document everything the investigator sees and takes, and involve counsel immediately — especially before responding to a Form 483. The response window is short and the response quality shapes whether the matter ends there or escalates to a warning letter.
Is a warning letter the end of the road?
No — it is FDA’s formal demand for correction, and a strong, evidence-backed response with completed corrective actions closes most of them. Ignored or answered weakly, warning letters escalate to import alerts, seizures, injunctions and consent decrees.
We import through Miami — does that change our compliance picture?
It concentrates it. Import-heavy operations face FDA at the border on every entry — screening, holds, detention risk — on top of the domestic rules. Entry data, registrations and supplier verification need to be airtight because they are tested shipment by shipment.